

# Sodium Oxybate for Narcolepsy with Cataplexy—A Cost-Effective Analysis

Lanting Lu<sup>FtGE</sup>, Chris Roome<sup>H</sup>, Lain Lang<sup>G&H</sup> and Ken Stein<sup>FtG</sup>

<sup>1</sup>Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK

2

## Methods

### Economic Evaluation

We estimate the cost-effectiveness of sodium oxybate comparing to the current treatment by following two cohorts of patients, one receiving standard treatment plus sodium oxybate and one continuing to receive standard treatment alone for a period of time. The economic evaluation estimates the average total cost for cohort of patients treated with sodium oxybate and the other cohort of patients with standard treatment, based on published data sources. Average quality-adjusted life years (QALYs) gained for the cohort treated with sodium oxybate and the cohort receiving standard treatment alone were based on the clinical trial data assessing QoL using scores obtained from the SF-36 instrument. We calculate the incremental cost-effectiveness ratio (ICER) to estimate the additional costs associated with the use of sodium oxybate to obtain a gain of one additional QALY when compared with standard treatment alone.

This ICER is given by the following formula:

$$ICER = \frac{Cost_{Sodium\ Oxybate} - Cost_{Standard\ treatment}}{QALY_{Sodium\ Oxybate} - QALY_{Standard\ treatment}}$$

We estimated the cost-effectiveness of sodium oxybate compared to standard treatment by assessing whether the ICER exceeded or remained below a willingness-to-pay threshold. If the ICER is no higher than a chosen threshold then sodium oxybate could be considered to be cost-effective when compared to standard treatment alone. In the UK, National Institute of Clinical Excellence (NICE) generally considers interventions with an ICER below the willingness-to-pay threshold of £20,000 per QALY gained to be cost-effective. Where the ICER is above £30,000 per QALY gained it is unlikely the intervention will be considered cost-effective, without additional exceptional factors supporting use (e.g. end-of-life care) [10].

### Overview

In this economic evaluation, we developed a Markov model to follow patients from commencement of treatment with sodium oxybate to the end of a five-year time horizon. The state transition diagram of the Markov model is illustrated in Supplementary Figure 1. To capture the differences in costs and utilities due to short-term events, such as non-response and patient withdrawal within the first three months, we used time-dependent parameters. The model takes an NHS perspective and incorporates utilities and costs associated with time spent on different treatments, time spent with significant side effects with sodium oxybate and death. We applied an annual discount rate of 3.5% to costs and benefits [10].

The population we considered consists of adults who suffer from narcolepsy with cataplexy and have derived inadequate benefit from treatment with antidepressants (as anti-cataplectic) and stimulants (for daytime sleepiness symptoms). Standard treatment used in clinical practice included using antidepressants such as clomipramine, fluoxetine and Venlafaxine for cataplexy symptoms, and stimulants including modafinil, dexamfetamine and methylphenidate for sleepiness symptoms. Sodium oxybate is assessed here as an add-on treatment i.e. used alongside stimulants and antidepressants. There were limitations in the data required for cost-effectiveness modelling reported in the published papers of sodium oxybate trials and so we have had to make a number of assumptions to permit comparison. These are detailed below.

### Structure of the Markov model

We simulated two cohorts of patients, one receiving standard treatment plus sodium oxybate and one continuing to receive standard treatment alone, from the point of entry to the end of a five-year horizon using a Markov model (Supplementary Figure 1). Three health states are defined in the model and we assume all patients, regardless of treatment, can only be in one state at any time-point. The three disease states defined are: (i) On Treatment: with maintained response (or in receipt of standard treatment alone and with ongoing inadequate response), (ii) Withdrawn from Treatment: patient withdrawal due to unsatisfactory response to sodium oxybate (for the group of patients with standard treatment, we assume the rate of withdrawal from standard treatment is zero throughout the comparison) and (iii) Dead: both cohorts of patients may die from other causes regardless of their treatment options and we have assumed likelihood of death is equal in each treatment arm. We have





$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$
	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$
$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$
	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$	$\frac{U_{\text{acc}}^{\text{acc}}}{U_{\text{acc}}^{\text{acc}}}$

Table 2: Values of parameters used in the decision model.



and on-treatment score was also quite small (0.025). This difference is less than the difference we obtained by applying the ESS-utility relationship regression equation. Thus, we consider that there are currently no data which would suggest that this method yields unreliable results for narcolepsy patients.

In our model we incorporated only one outcome measure from the clinical trial data, the effect of treatment on ESS. It is likely other measures reported in the trials could impact on QoL, such as number of cataplexy attacks per week or nocturnal sleep quality, but we found no information allowing us to relate such findings to impact on cataplexy (or of resolution of cataplexy or improvement in nocturnal sleep quality), which could be related to QALY changes. Our sensitivity analyses show outcomes associated with assuming the widest possible range of utilities associated with this condition, going from the most severe end of reported utilities to total resolution. It is unlikely that the inclusion of additional data on cataplexy would represent cases not already assessed in the sensitivity analyses but the absence of these data introduces additional uncertainty to our model.

### Implications

On the basis of current costs, sodium oxybate is unlikely to be cost-effective as an add-on treatment for patients who respond inadequately to standard treatment with stimulants and antidepressants. Although, it is recognised that measure of improvement in utilities used in the current model may be an underestimation of the reality.

There remains substantial uncertainty about the quality of life impact of this chronic rare condition and further research is necessary to permit future analyses to consider the cost-effectiveness of sodium oxybate. Current understanding of the impact of cataplexy is particularly limited, as is available evidence on the long-term course of the condition.

### References

1. Dauvilliers Y, Arnulf I, Mignot E (2007) Narcolepsy with cataplexy. *Lancet* 369: 499-511.
2. Ohayon MM, Priest RG, Caulet M, Guilleminault C (1996) Hypnagogic and hypnopompic hallucinations: pathological phenomena? *Br J Psychiatry* 169: 459-467.
3. Wise MS (1998) Childhood narcolepsy. *Neurology* 50: S37-S42.
4. UCB Pharma Ltd. Sodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) - Resubmission to Scottish Medicines Consortium 2007 10 August 2007.
5. Weaver TE, Cuellar N (2006) A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. *Sleep* 29: 1189-1194.

6. European Medicines Evaluation Agency (2007) Scientific discussion of the European Public Assessment report for Xyrem®
7. The U.S. Xyrem® (2002) Multicenter Study Group. A Randomized, Double Blind, Placebo-Controlled Multicenter Trial Comparing the Effects of Three Doses of Orally Administered Sodium Oxybate with Placebo for the Treatment of Narcolepsy. *Sleep* 25: 42-49
8. The U.S. Xyrem® (2003) Multicenter Study Group. A 12-month, Open-Label, Multicenter Extension Trial of Orally Administered Sodium Oxybate for the Treatment of Narcolepsy. *Sleep* 26: 31-35
9. The Xyrem® (2005) International Study Group. A Double-Blind, Placebo-Controlled Study Demonstrates Sodium Oxybate Is Effective for the Treatment of Excessive Daytime Sleepiness in Narcolepsy. *Journal of Clinical Sleep Medicine* 1: 391-397.
10. National Institute for Health and Clinical Excellence (2008) Guide to the Methods of Technology Appraisal. London: NICE.
11. Office for National Statistics (ONS). Interim Life Tables, United Kingdom
12. Hayduk R, Mittle M (2001) Sodium Oxybate Therapy Improves the Quality of Life of Narcolepsy Patients. *Sleep* 24 abstract supplement: A328
13. Dodel R, Peter H, Spottke A, Noelker C, Althaus A, et al. (2007) Health-related quality of life in patients with narcolepsy. *Sleep Med* 8: 733-741.
14. Black J, Houghton WC (2006) Sodium oxybate improves excessive daytime sleepiness in narcolepsy. *Sleep* 29: 939-946
15. Teixeira VG, Faccenda JF, Douglas NJ (2004) Functional status in patients with narcolepsy. *Sleep Med* 5: 477-483
16. Ara R, Brazier J (2008) Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). *Value Health* 11: 1131-1143
17. McDaid C, Griffin S, Weatherly H, Durée K, van der Burgt M, et al. (2009) Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. *Health Technol Assess* 13: 1-274.
18. Department of Health (UK) NHS Reference Costs 2009. London: Department of Health.
19. Joint Formulary Committee (2010) British National Formulary No. 59. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
20. Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, et al. (1999) Health-related quality of life effects of modafinil for treatment of narcolepsy. *Sleep* 22: 757-765
21. Daniels E, King MA, Smith IE, Shneerson JM (2001) Health-related quality of life in narcolepsy. *J Sleep Res* 10: 75-81.
22. Vignatelli L, D'Alessandro R, Mosconi P, Ferini-Strambi L, Guidolin L, et al. (2004) Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey. *Sleep Med* 5: 467-475
23. Kind P, Hardman G, Macran S (1999) UK population norms for EQ-5D. York: Centre for Health Economics, University of York.